Ironwood Pharmaceuticals, Inc.
IRWD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -8.00 | 0.00 | -0.17 | 0.01 |
| FCF Yield | 14.67% | 10.30% | 14.31% | 13.83% |
| EV / EBITDA | 12.13 | -2.60 | 6.40 | 7.49 |
| Quality | ||||
| ROIC | 0.40% | -258.69% | 16.10% | 56.36% |
| Gross Margin | 97.85% | 100.00% | 99.65% | 99.63% |
| Cash Conversion Ratio | 117.67 | -0.18 | 1.56 | 0.50 |
| Growth | ||||
| Revenue 3-Year CAGR | -5.06% | 2.28% | 1.77% | -1.15% |
| Free Cash Flow Growth | -43.54% | -33.06% | 4.59% | 56.67% |
| Safety | ||||
| Net Debt / EBITDA | 5.10 | -0.67 | -0.92 | -0.62 |
| Interest Coverage | 2.82 | -43.71 | 32.95 | 7.46 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 1.13 | 0.00 |
| Cash Conversion Cycle | -301.00 | 106.45 | 300.07 | -123.48 |